Viola Brands Goes Nationwide in Canada with

  • Avicanna’s partnership with Viola brings the equity-driven brand founded by NBA veteran Al Harrington in Canada for the first time.
  • Initial products will be available nationally on the Medical Cannabis by Shoppers online platform, followed by adult use channels including Ontario and New Brunswick.

TORONTO, Nov. 09, 2021 (GLOBE NEWSWIRE) – Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN)
(OTCQX: AVCNF) (FSE: 0NN), a Canadian biopharmaceutical company focused on the development of plant-derived cannabinoid products, today announced the distribution of Viola cannabis products across Canada on the Medicinal cannabis by buyers online platform, a subsidiary of Shoppers Drug Mart Inc. ™, Canada’s largest health, beauty and convenience store retailer. The well-established fairness-focused brand will also be available on adult usage channels including Ontario and New Brunswick shortly.

Founded in 2011 by NBA veteran Al Harrington, Viola is one of the leading licensed producers and wholesalers of premium cannabis products in the United States with a presence in 4 states. Viola’s mission is to increase minority representation and provide better employment opportunities to black communities and others under-represented in the cannabis industry. Viola cannabis products available at Medicinal cannabis by buyers The platform includes THC and CBD offerings starting with disposable live terpene vaporizers and expanding into other categories including 510 cartridges and concentrates.

“We are excited to launch in Canada with our partner Avicanna, who shares our vision to increase representation and promote fairness within the cannabis industry,” said Al Harrington, Co-Founder and CEO of Viola Brands. “And we look forward to having Viola’s premium products available at Medical Cannabis by Shoppers.

“Today, Canada’s incredible diversity is not well represented by existing brands and, through this multi-level partnership with Viola, we seek to fill this gap, provide much needed minority representation and expand the Al’s vision to Canadian consumers, ”said Aras Azadian, CEO, Avicanna Inc.“ Additionally, the launch of Viola’s premium products in Canada as part of our distribution agreement with Medical Cannabis by Shoppers Drug Mart Inc. . ™ will be a huge victory for Canadians, as the products will be immediately available across the country. “

Canadians will now have access for the first time to Viola’s award-winning cannabis products through a national chain. Through the company’s multi-level partnership with Viola, Avicanna is responsible for managing the overall marketing of all Viola branded products in Canada through its manufacturing, distribution and sales infrastructure. Additional Viola cannabis products will be available in multiple provinces through adult use channels offering multiple consumption options via portfolio expansion slated for late 2021 with initial listings approved in New Brunswick and Ontario. .

About Viola
Founded in 2011 by NBA veteran Al Harrington, Viola is one of the nation’s leading licensed producers and wholesalers of premium cannabis products. The brand takes its name and is inspired by Al’s grandmother who suffers from glaucoma and diabetes, finding solace in cannabis remedies. Viola has incorporated the latest cutting edge technologies with its own exclusive procedures designed for each step of the cultivation, extraction and production process. The company is known for its wide variety of products, from high-quality flowers to premium butane extracts, and operates in California, Colorado, Michigan, Oregon and Oklahoma.

Through education, fair offerings, radiation and incubation programs, Viola’s mission is to increase minority representation, facilitate community building, and provide better opportunities for employment for blacks and other minority communities in cannabis. Viola intends to expand Viola’s reach in Canada with educational initiatives to increase awareness of the safe use of cannabis.

About Avicanna Inc.
Avicanna is a Canadian commercial-stage biopharmaceutical company and an established leader in research, development and evidence-based products on cannabinoids for the global consumer, medical and pharmaceutical market segments. Avicanna conducts her research in Canada, including its R&D headquarters at the Johnson & Johnson Innovation Center, JLABS @ Toronto, Canada, located in the MaRS Discovery District, and in collaboration with leading Canadian academic and medical institutions. Avicanna has established a cutting-edge scientific platform comprising advanced R&D and clinical development which has led to the commercialization of over twenty products in four main market segments:

  • RHO Phyto ™: these medical and wellness products are an advanced line of pharmaceutical grade cannabis products containing different ratios of CBD and THC. The product portfolio contains a comprehensive product form including oral, sublingual, topical and transdermal deliveries that have controlled dosage, improved absorption, and stability studies supported by preclinical data. These products are developed using pharmaceutical drug development processes and are supported by preclinical data. The advanced form is marketed with education and training of consumers, patients and the medical community.
  • Pura H & W ™: these registered and clinically tested cosmetics include a portfolio of functional dermo-cosmetic and topical products for CBD consumers.
  • Aureus ™: As part of the vertical integration of Avicanna based in Santa Marta, Colombia, its raw materials business units are primarily focused on providing a constant source of cannabinoid raw materials for Avicanna and the food, cosmetic, medical and pharmaceutical needs of its global partner. Aureus brand products are grown, extracted and manufactured by Avicanna subsidiaries in Colombia, including SMGH which is GACP and USDA certified organic and where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients in an economical, biological manner. and sustainable and include a range of CBD, THC and rare cannabinoids such as CBG extracts and standardized seeds. The company is well positioned to be a global supplier of demand for cannabinoid raw materials and has already successfully exported its products to more than 11 countries on 4 continents.
  • Pharmaceutical pipeliborn : Leveraging the company’s science platform, vertical integration, and real-world evidence, Avicanna has established a pipeline of indication-specific cannabinoid drug candidates that are in various stages of development. clinical and marketing. Avicanna’s drug candidates are in the preclinical stage and are dedicated to providing solutions to unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders.

Stay connected

For more information on Avicanna, visit, call 1-647-243-5283 or contact Ivana Maric by email at [email protected]

The company posts updates via videos from the company’s official YouTube channel

Caution regarding forward-looking information and statements

This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “plan”, “intend”, “believe”, “anticipate”, “estimate”, “May”, “may”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These forward-looking statements are only predictions. Various assumptions have been used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made. made, such as current and future market conditions, future regulatory environment, and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management considers relevant and reasonable in the circumstances that could cause events, results, level of activity, performance, actual prospects, opportunities or achievements differ materially from those projected in forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in required commodity prices, competition, effects and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 15, 2020 (the “FIA) And filed with Canadian securities regulatory authorities, available on the Company’s Issuer Profile on SEDAR at The Company cautions that the list of risks, uncertainties and other factors described in the Annual Information Form is not exhaustive and that other factors could also adversely affect its results. Readers are urged to carefully consider risks, uncertainties and assumptions when evaluating forward-looking statements and are cautioned not to place undue reliance on such information. The Company has no obligation and expressly disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by laws on applicable securities.

A photo accompanying this announcement is available at


Leave A Reply